Soligenix Shares Jump 110% Pre-Market on Bundibugyo Vaccine Platform with Hawai’i Partnership
SNGX•Soligenix shares surged 110% pre-market over $1 for the first time in a month as investors bet on its thermostable Bundibugyo virus vaccine platform co-developed with the University of Hawai’i. Short interest hit a six-month high and FDA orphan drug status for related strains could accelerate clinical development pending funding.
1. Pre-Market Surge
Soligenix shares jumped 110% in pre-market trading to break above $1 for the first time in a month as investors reacted to new vaccine platform developments.
2. Thermostable Bundibugyo Vaccine Platform
The thermostable single-vial Bundibugyo virus vaccine developed with the University of Hawai’i can be stored at ambient temperature and has FDA orphan designations for related Ebola strains, enhancing distribution logistics and exclusivity.
3. Elevated Short Interest
Short interest reached a six-month high, indicating increased speculative positioning ahead of potential clinical milestones and funding announcements.
